PRISM

GENE FORUM

DECEMBER 4-6 | PARIS, FRANCE

2ND INTERNATIONAL CONFERENCE ON

HUMAN GENE THERAPY

DECEMBER 04-06, 2024



www.genetherapyconference.com

DAY 1 December 04, 2024

12:40-12:50	Opening Speech: Tristan Jervis, Impact Shine Communications, UK
Time Zone: Paris	**Re-Engineering and Rewriting Genetics with Gene therapy: Past, Present & Future Approaches**
12:50-13:00 20:50-21:00 (JST)	Title: gBoostTM, a Cell-Selective Gene Expression Enhancer (E-Poster) ***Mak Inoue,*** *Infirmacea Inc, Japan*
13:00-13:30 12:00-12:30 (GMT)	Title: Issues and Crisis Management – Staving Off Disastrous Consequences: Preparedness and Strategic Approaches: ***Tristan Jervis,*** *Impact Shine Communications, UK*
13:30-14:00	Title: Unlocking Capital for Gene Therapy: Overcoming Financial Bottlenecks ***Adrien Clavairoly,*** *AdBio Partners, France*
14:00-14:30	Title: Gene Therapies for Rare Diseases: Facing Obstacles and Limitations ***Antoni Matilla-Dueñas,*** *Biointaxis, Spain*
14:30-15:00 13:30-14:00 (GMT)	Title: Next Generation of Programmable, Intuitive, Vectors for Clinical Applications of Gene Therapy ***Farzin Farzaneh,*** *ViroCell Biologics, UK*
15:00-15:30	BREAK
15:30-16:00 09:30-10:00 (EST)	Title: Enrollment in Gene Therapy Clinical Trails; Strategies and Challenges ***Chrissy Burton & Alicia M. Gomez,*** *BridgeBio, USA*
16:00-16:30 10:00-10:30 (EST)	Title: AAV Safety and the Need for Better Data Sharing in Gene Therapy Clinical Trials ***Genevieve Laforet,*** *Aspa Therapeutics, USA*
16:30-17:00 10:30-11:00 (EST)	Title: Advancing Gene Therapy Trials with Real-World Evidence and External Controls ***Megan Sutton,*** *Formerly LEXEO Therapeutics, USA*
17:00-17:30 11:00-11:30 (EST)	Title: Development of Capsid-Modified NextGen AAV Vectors, and the Need for Beyond Capsid-Modifications ***Arun Srivastava,*** *University of Florida College of Medicine, USA*

DAY 2 December 05, 2024

Gene Therapeutics: Clinical Approaches and Applications

12:30-13:00	Title: CNS Gene Therapy : Recent Advances and Challenges ***Nathalie Cartier,*** *Asklepios BioPharmaceutical, France*
13:00-13:30	Title: Lessons Learned from 2 Decades of GT Using AAV as a Therapeutic Modality: Key Elements to Consider Promoting Successful Development ***Anne Douar,*** *Vivet Therapeutics, France*
13:30-14:00	Title: New Strategies for Allogeneic Cellular Immunotherapies ***Olivier Negre,*** *Smart Immune, France*
14:00-14:30	Title: CAR-Tregs Therapies to Treat Immunological Disorders ***Sophie Blondel,*** *Taegia, France*
14:30-15:00	BREAK
15:00-15:30	Title: Scaling New Heights in the Fight Against Heart Disease ***Natasha Paterson,*** *Tenaya Therapeutics, USA*
15:30-16:00 09:30-10:00 (EST)	Title: Prime Editing Permits to Correct Point Mutations Responsible for Many Muscular Dystrophies ***Jacques P. Tremblay,*** *Laval University, Canada*
16:00-16:30 10:00-10:30 (EST)	Title: Placebo Control Arms in Rare Diseases Clinical Trials: Main Considerations ***Mitra Tavakkoli,*** *Senior Biotech Consultant, USA*
16:30-17:00	Title: The Role of Regulatory CMC in the Development of a GT ***Gabriel Bohl,*** *ICON Plc, France*
17:00-17:30 08:00-08:30 (PST)	Title: FDA Regulations ***Binh Nguyen,*** *Wynngate Corporation, USA*

DAY 3 December 06, 2024

Unlocking Health Mysteries: Analytics, Manufacturing and Commercialization of Stratergies

14:00-14:30	Title: Dual AAV Manufacturing & Control Strategy ***Christine Le Bec,*** *Sensorion, France*
14:30-15:00 13:30-14:00 (GMT)	Title: Advancing Gene Therapeutics into GMP Compliant Commercial Manufacturing ***James Drinkwater,*** *Franz Ziel GmbH, UK*
15:00-15:30	Title: Commercialization and Alternative Payment Models for Specialty Pharmaceuticals in The USA ***Jeff Chaffin,*** *Miles Payer Strategy, USA*
15:30-16:00 09:30-10:00 (EST)	Title: Mitigating Immune Responses to AAV Vector-Mediated Gene Transfer ***Hildegund Ertl,*** *The Wistar Institute, USA*
16:00-16:30 09:00-09:30 (CST)	Title: Cytokine Gene Therapy for Treatment of a Brain Tumor ***Terry Lichtor,*** *Professor, Rush University, USA*
16:30-17:00 15:30-16:00 (GMT)	Title: Digital Twins and AI to Support Real Time Batch Manufacturing ***Shayoni Dutta,*** *GSK, UK*
17:00-17:30	Title: Translate Core Technologies into Pioneering Manufacturing Technologies to Accelerate the Time-To-Market for Gene Therapies ***Pascale Berthet,*** *Antleron B. V, France*

PRISM

Professional Conference Organizers

Prism Scientific Services Pty Ltd., a premier conference organizer, envisions a sustainable future for the Biotechnology and Pharmaceutical industry. Our goal is to unite experts and stakeholders through conferences, fostering collaboration and advancing sustainable practices. Committed to curating conferences on Gene Theraphy and Advanced Gene-editing technologies, we catalyze the industry's development. Emphasizing interdisciplinary collaboration, our events address complex challenges. Dedicated to therapeutics, we minimize footprints and promote safety and efficacy of gene therapy, inspiring market approval. As catalysts for positive change, we guide the Biotechnology and Pharmaceutical industry towards development technologies, cost effectiveness and commmercialization for a responsible future in conferences that prioritize sustainable development.

If you are interested in forming a partnership with us for the planning and organization of conferences and events worldwide, please don't hesitate to contact us via email at writeus@scientificprism.com or by phone at +61 416000202. Our services extend to facilitating conferences anywhere in the world, and we look forward to the opportunity to discuss your specific needs and requirements.

We wish to see you at
GENE FORUM - 2025

Prism Scientific Services Pty Ltd
302/480 Collins Street, Melbourne, VIC 3000, Australia
https://www.Scientificprism.com

Contact Information:
committee@energyconferenceaustralia.com
info@energyoceania.com

Phone: +61 390163202
Website: www.energyconferenceaustralia.com

PRISM